BEIJING TONGRENTANG CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.9 CNY | +5.07% |
|
+1.66% | -20.11% |
| Mar. 28 | Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Companyâs main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
42.9
CNY
Average target price
53.25
CNY
Spread / Average Target
+24.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.11% | 8.12B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600085 Stock
- News Beijing Tongrentang Co., Ltd
- China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug
